Andreas Hüttmann - Concepedia

Author

Andreas Hüttmann

Also Known As

A HUTTMANN, A Huttmann, A Hüttmann, A. Huttmann, A. Hüttmann, Andreas Huttmann, Andreas Hüttmann, Andreas Hüttmann, Huttmann, A., Jan Dürig

192

Publications

8.2K

Citations

H-Index

Concepts

All Affiliations

Essen University Hospital University of Duisburg-Essen Goethe University Frankfurt University Hospital Münster Charité - Universitätsmedizin Berlin

About

Andreas Hüttmann is an author at Essen University Hospital specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	24	2.6K
2	Health Sciences	11	11	1.7K
3	Engineering	1	1	223
4	Natural Sciences	1	1	51
5	Biochemistry	1	1	20

Andreas Hüttmann

Publications

7.1K

Citations

H-Index

Page 1

	Year	Citations
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, The Lancet	2018	707
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma David M. Kurtz, Florian Scherer, Michael C. Jin, Journal of Clinical Oncology	2018	472
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation Nicola Gökbuget, Daniel Stanze, Joachim Beck, Blood	2012	451
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial Christoph Röllig, Hubert Serve, Andreas Hüttmann, The Lancet Oncology Sorafenib Versus PlaceboHematological MalignancyOncologyMixed-phenotype Acute LeukemiaHematology	2015	395
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group Peter Borchmann, Helen Goergen, Carsten Kobe, The Lancet Positron Emission TomographyAdvanced-stage HodgkinLymphoid NeoplasiaSurgical OncologyOncologic Imaging	2017	372
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA David M. Kurtz, Joanne Soo, Lyron Co Ting Keh, Nature Biotechnology OncologyEnhanced DetectionSomatic VariantTumor HeterogeneityMedicine	2021	332
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial Dieter Hoelzer, Jan Walewski, Hartmut Döhner, Blood	2014	296
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, Annals of Oncology	2021	240
Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial Ulrich Dührsen, Stefan Müller, Bernd Hertenstein, Journal of Clinical Oncology	2018	238
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction David M. Kurtz, Mohammad Shahrokh Esfahani, Florian Scherer, Cell OncologyEngineeringData ScienceMedicinePredictive Analytics	2019	223

Page 1